BioNeutra Global Corporation, together with its subsidiaries, engages in the research and development, production, and commercialization of food ingredients for nutraceutical, functional, and mainstream foods and beverages with a focus on oligosaccharides.
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has BioNeutra Global's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BGA's share price has been volatile over the past 3 months.
7 Day Return
CA Personal Products
1 Year Return
CA Personal Products
Return vs Industry: BGA underperformed the Canadian Personal Products industry which returned -1.4% over the past year.
Return vs Market: BGA underperformed the Canadian Market which returned -11.5% over the past year.
Price Volatility Vs. Market
How volatile is BioNeutra Global's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StBioNeutra Global (CVE:BGA) Has Debt But No Earnings; Should You Worry?
1 month ago | Simply Wall StHow Much is BioNeutra Global Corporation's (CVE:BGA) CEO Getting Paid?
2 months ago | Simply Wall StSome BioNeutra Global (CVE:BGA) Shareholders Have Copped A Big 68% Share Price Drop
Is BioNeutra Global undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BGA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BGA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BGA is unprofitable, so we can't compare its PE Ratio to the Personal Products industry average.
PE vs Market: BGA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BGA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BGA is overvalued based on its PB Ratio (1.5x) compared to the CA Personal Products industry average (1.3x).
How is BioNeutra Global forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioNeutra Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of BGA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- BioNeutra Global competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Household industry.
How has BioNeutra Global performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BGA is currently unprofitable.
Growing Profit Margin: BGA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BGA is unprofitable, and losses have increased over the past 5 years at a rate of -59.7% per year.
Accelerating Growth: Unable to compare BGA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGA is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (18.7%).
Return on Equity
High ROE: BGA has a negative Return on Equity (-261.83%), as it is currently unprofitable.
How is BioNeutra Global's financial position?
Financial Position Analysis
Short Term Liabilities: BGA's short term assets (CA$20.6M) do not cover its short term liabilities (CA$22.5M).
Long Term Liabilities: BGA's short term assets (CA$20.6M) exceed its long term liabilities (CA$6.7M).
Debt to Equity History and Analysis
Debt Level: BGA's debt to equity ratio (159.5%) is considered high.
Reducing Debt: BGA's debt to equity ratio has increased from 2.8% to 159.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BGA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BGA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 26.4% per year.
What is BioNeutra Global current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BGA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BGA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BGA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BGA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BGA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Jianhua Zhu, Ph.D., is Founder and has been Chief Executive Officer of BioNeutra Global Corporation since October 2014 and serves as its President. Dr. Zhu has been Chief Executive Officer and Director ...
CEO Compensation Analysis
Compensation vs Market: Jianhua's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD173.55K).
Compensation vs Earnings: Jianhua's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||0.17yr||no data||no data|
|Vice-President of Communications & HR||2.17yrs||no data||no data|
|Vice President of Sales & Marketing||1.5yrs||no data||no data|
|Corporate Secretary||no data||no data||no data|
Experienced Management: BGA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Chairman||0.25yr||no data||no data|
|Independent Director||0.92yr||CA$66.02k||0.79% CA$55.3k|
|Director||0.92yr||no data||no data|
|Director||0.92yr||no data||no data|
Experienced Board: BGA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BioNeutra Global Corporation's company bio, employee growth, exchange listings and data sources
- Name: BioNeutra Global Corporation
- Ticker: BGA
- Exchange: TSXV
- Industry: Personal Products
- Sector: Household
- Market Cap: CA$6.967m
- Shares outstanding: 46.45m
- Website: https://www.bioneutra.ca
Number of Employees
- BioNeutra Global Corporation
- 9608-25 Avenue NW
- T6N 1J4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BGA||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Oct 2015|
BioNeutra Global Corporation, together with its subsidiaries, engages in the research and development, production, and commercialization of food ingredients for nutraceutical, functional, and mainstream foods and beverages with a focus on oligosaccharides. Its lead product is VitaFiber, an isomalto-oligosaccharide functional and health food ingredient that offers low calorie and soluble prebiotic fiber for human digestive health. The company serves small and medium enterprises, and various food and beverage manufacturers in Canada, the United States, Europe, Australia, New Zealand, and internationally. It also provides VitaFiber through Amazon.com and Shopify.com, as well as other direct-to-consumer retailers. BioNeutra Global Corporation is based in Edmonton, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/08 00:13|
|End of Day Share Price||2020/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.